Stocks and Investing Stocks and Investing
Tue, June 21, 2022

Charles Duncan Maintained (ACAD) at Buy with Decreased Target to $26 on, Jun 21st, 2022


Published on 2024-10-27 21:33:44 - WOPRAI, Charles Duncan
  Print publication without navigation


Charles Duncan of Cantor Fitzgerald, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $37 to $26 on, Jun 21st, 2022.

Charles has made no other calls on ACAD in the last 4 months.



There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 3 agree with Charles's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Vamil Divan of "Mizuho" Maintained at Hold with Decreased Target to $27 on, Tuesday, April 19th, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Hold with Decreased Target to $24 on, Monday, March 7th, 2022
  • Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $31 on, Tuesday, March 1st, 2022


These are the ratings of the 2 analyists that currently disagree with Charles


  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy and Increased Target to $31 on, Wednesday, March 16th, 2022
  • Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $35 on, Tuesday, March 1st, 2022
Contributing Sources